title: A prodrug resistance mechanism is involved in colibactin biosynthesis and cytotoxicity.
abstract: Commensal Escherichia coli residing in the human gut produce colibactin, a small-molecule genotoxin of unknown structure that has been implicated in the development of colon cancer. Colibactin biosynthesis is hypothesized to involve a prodrug resistance strategy that entails initiation of biosynthesis via construction of an N-terminal prodrug scaffold and late-stage cleavage of this structural motif during product export. Here we describe the biochemical characterization of the prodrug synthesis, elongation, and cleavage enzymes from the colibactin biosynthetic pathway. We show that nonribosomal peptide synthetases ClbN and ClbB assemble and process an N-acyl-D-asparagine prodrug scaffold that serves as a substrate for the periplasmic D-amino peptidase ClbP. In addition to affording information about structural features of colibactin, this work reveals the biosynthetic logic underlying the prodrug resistance strategy and suggests that cytotoxicity requires amide bond cleavage.
authors: Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.
authors: Carolyn A
authors: CA
authors: Brotherton
authors: Emily P
authors: EP
authors: Balskus
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008968:Molecular Conformation; D010453:Peptide Synthases / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D061065:Polyketides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011355:Prodrugs / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D010455:Peptides; D061065:Polyketides; D011355:Prodrugs; C569566:colibactin; D010453:Peptide Synthases